Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; sodium lauryl sulfate; ethylcellulose; polysorbate 80; magnesium stearate; hyprolose; purified talc; iron oxide yellow; povidone; light magnesium oxide; propylene glycol; titanium dioxide - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: mannitol; magnesium stearate; diethyl phthalate; ethylcellulose; hypromellose phthalate; purified talc; iron oxide yellow; light magnesium oxide; povidone; sodium starch glycollate type a; titanium dioxide - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; sodium stearylfumarate; hypromellose phthalate; calcium hydroxide; hypromellose; purified talc; titanium dioxide; dibutyl sebacate; hyprolose; mannitol - rabeprazole sandoz is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment of gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole sandoz is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: heavy magnesium oxide; diacetylated monoglycerides; mannitol; iron oxide yellow; hypromellose phthalate; titanium dioxide; light magnesium oxide; purified talc; magnesium stearate; ethylcellulose; hyprolose; propylene glycol; butan-1-ol; allura red ac aluminium lake; industrial methylated spirit; ethanol; shellac; strong ammonia solution; sulfuric acid - treatment and prevention of relapse of gastro-oesophageal reflux disease. symptomatic treatment of gastro-oesophageal reflux disease. treatment of duodenal ulcers. treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; propylene glycol; povidone; sodium lauryl sulfate; magnesium stearate; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; light magnesium oxide; purified talc; hyprolose; polysorbate 80; ethylcellulose - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; iron oxide yellow; mannitol; diethyl phthalate; hypromellose phthalate; sodium starch glycollate type a; light magnesium oxide; magnesium stearate; titanium dioxide; purified talc; povidone - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; iron oxide yellow; sodium starch glycollate type a; light magnesium oxide; diethyl phthalate; magnesium stearate; titanium dioxide; hypromellose phthalate; mannitol; povidone; purified talc - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; purified talc; diethyl phthalate; povidone; hypromellose phthalate; titanium dioxide; magnesium stearate; mannitol; sodium starch glycollate type a; ethylcellulose; iron oxide red - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: sodium stearylfumarate; purified talc; hyprolose; hypromellose; iron oxide yellow; mannitol; iron oxide red; dibutyl sebacate; hypromellose phthalate; titanium dioxide; calcium hydroxide - rabeprazole sandoz is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment of gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole sandoz is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; hyprolose; ethylcellulose; magnesium stearate; purified talc; crospovidone; mannitol; titanium dioxide; hypromellose phthalate; iron oxide yellow - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.